---

Highlights of October 2021

1. Eli Lilly and Cipla enter into strategic partnership in India to enhance access to Lilly key diabetes products.
2. Exelixis In-Licenses Second Anti-Cancer Compound from Aurigene (a wholly owned subsidiary of Dr. Reddy’s Laboratories Ltd.).
3. Merck & Divis' Covid-19 antiviral pill, Molnupiravir, reduced the risk of hospitalization or death by 50 per cent. Merck has also struck licensing agreements with Sun Pharmaceuticals, Cipla, Dr Reddy’s Laboratories among others to market the drug in India and +100 LMIC countries.
4. Lipocine and Antares Pharma have entered into an exclusive license agreement to develop and commercialize TLANDO in the US.
5. Takeda buys out collaborator GammaDelta Therapeutics for solid tumor pipeline.
6. ATDBio acquired by Biotage to provide platform for further growth.
7. Atlas Antibodies enters agreement with T-Cure Bioscience.
8. Schrödinger inks deal to discover novel orexin receptor with Centessa unit.
9. Immusoft inks deal with Takeda on rare neurometabolic disorders.
10. Bio-Thera partners with Pharmapark in Russia/CIS on BAT2206, a Stelara biosimilar.
11. Inotiv acquires drug discovery company Plato BioPharma in US$15 Million deal.
12. Xencor Enters Global Collaboration and License Agreement With Janssen to Advance Plamotamab and XmAb CD28 Bispecific Antibody Combinations for the Treatment of Patients With B-Cell Malignancies.